Stockscreener 앱 받기
16.70
4.95%
-0.87
전일 마감가:
$17.57
열려 있는:
$17.38
하루 거래량:
346.23K
Relative Volume:
0.88
시가총액:
$628.27M
수익:
$50.00M
순이익/손실:
$-58.44M
주가수익비율:
-8.5523
EPS:
-1.9527
순현금흐름:
$-57.73M
1주 성능:
-2.05%
1개월 성능:
+5.03%
6개월 성능:
+12.38%
1년 성능:
+51.96%
1일 변동 폭
$16.50
$17.71
1주일 범위
$15.81
$17.79
52주 변동 폭
$8.60
$17.79
Contineum Therapeutics Inc Stock (CTNM) Company Profile
명칭
Contineum Therapeutics Inc
전화
(858) 333-5280
주소
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
16.70 | 602.69M | 50.00M | -58.44M | -57.73M | -1.9527 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-09-25 | 개시 | Leerink Partners | Outperform |
| 2025-06-20 | 개시 | William Blair | Outperform |
| 2024-10-22 | 개시 | Robert W. Baird | Outperform |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-30 | 개시 | Stifel | Buy |
모두보기
Contineum Therapeutics Inc 주식(CTNM)의 최신 뉴스
Balyasny Asset Management L.P. Expands Stake in Contineum Therap - GuruFocus
Contineum (CTNM) Results at a Glance: The Bottom-Line Figure Beats Its Comparison in Latest Trading; Closing Move - vinanet.vn
Morgan Stanley Adjusts PT on Contineum Therapeutics to $18 From $16, Keeps Equalweight Rating - marketscreener.com
Contineum Therapeutics, Inc. Stock 12‑Month Price Target Raised to $23.14, Implies 63% Upside - TradingView
Contineum Therapeutics (CTNM) Slides 7.25% to $14.19 — Testing Key Support After Sharp Sell-OffFair Value Gap - vinanet.vn
Stifel Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Contineum Therapeutics (NASDAQ:CTNM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Trading Down 4.9%What's Next? - marketbeat.com
Contineum Therapeutics (CTNM): Balyasny group reports 7.14% stake in 13G/A filing - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Trading 6.8% HigherShould You Buy? - MarketBeat
CTNM Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Share GainCFO Commentary Report - Vinanet
CTNM Q2 2026 Earnings: Narrower-than-Expected Loss Lifts SharesGross Profit Margin - Vinanet
Contineum Therapeutics (CTNM) Pulls Back 3.66% to $14.49 as Support Level Comes into FocusSingle Stock ETF - dars.gov.et
(CTNM) Risk Channels and Responsive Allocation - Stock Traders Daily
Form 4 Contineum Therapeutics Inc For: 3 August By Investing.com - Investing.com Nigeria
Contineum Therapeutics CEO Stengone sells $40,029 of common stock By Investing.com - Investing.com Nigeria
Contineum Therapeutics (CTNM) CEO sells 2,500 shares after option exercise - Stock Titan
CTNM (CTNM) insider schedules 2,500-share stock sale after recent 10b5-1 trades - Stock Titan
CTNM (CTNM) insider Daniel Lorrain files to sell 9,520 common shares - Stock Titan
Contineum Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Perceptive Advisors LLC Has $16.40 Million Stake in Contineum Therapeutics, Inc. $CTNM - MarketBeat
RBC Capital Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
RBC Lifts Price Target on Contineum Therapeutics to $23 From $22, Keeps Outperform, Speculative Risk - marketscreener.com
Contineum reports $15.2 million second quarter loss - Quiver Quantitative
Contineum Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary - TradingView
Contineum Therapeutics reports Q2 2026 net loss $15.2M; cash and marketable securities $236.6M - TradingView
CTNM|Contineum Therapeutics Inc|Price:17.190|Chg%:+1.170 - TradingKey
Contineum Therapeutics, Inc. Revenue Breakdown – NASDAQ:CTNM - TradingView
BlackRock (CTNM stakeholder) reports 2.0M-share beneficial position in Therapeutics Inc - Stock Titan
CTNM|Contineum Therapeutics Inc|Price:15.390|Chg%:-0.510 - TradingKey
Contineum Therapeutics Inc (CTNM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Contineum Therapeutics Inc (CTNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Contineum Therapeutics Inc (CTNM) Institutional Confidence - TradingKey
Contineum Therapeutics Inc (CTNM) Balance Sheet - TradingKey
Contineum Therapeutics Market Sentiment - Benzinga España
TradingKey - TradingKey
Contineum Therapeutics Inc (CTNM) Income Statement - TradingKey
CTNM|Contineum Therapeutics Inc|Price:13.835|Chg%:-0.225 - TradingKey
Millennium Management LLC Reduces Stake in Contineum Therapeutics Inc - GuruFocus
Contineum Therapeutics Inc. (CTNM) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Surprise, Stock Pulls BackEPS Growth Rate - dars.gov.et
Baird Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - MSN
Contineum Therapeutics (CTNM) stake at 2.8% in Millennium 13G/A update - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Is In A Good Position To Deliver On Growth Plans - Moomoo
Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ: CTNM) Stock Price, News & Analysis - Kalkine
Liquidity Mapping Around (CTNM) Price Events - Stock Traders Daily
Contineum Therapeutics Updates Strategy, Highlights PIPE-791 Leadership - The Globe and Mail
Contineum Therapeutics updates corporate presentation; highlights PIPE-791 progress, cash runway through mid-2029 - TradingView
Contineum Therapeutics (NASDAQ: CTNM) details PIPE-791 IPF trial and PIPE-307 deal - Stock Titan
Contineum Therapeutics (CTNM) Slips Amidst Sector Pressures – Key Levels in FocusCash Flow Strong Stocks - dars.gov.et
Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock - Investing.com UK
Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock By Investing.com - Investing.com Nigeria
Contineum Therapeutics Inc (CTNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Contineum Therapeutics Inc 주식 (CTNM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Stengone Carmine N. | CEO and President |
Aug 03 '26 |
Sale |
16.01 |
2,500 |
40,029 |
17,217 |
0.86%
0.31%
자본화:
|
볼륨(24시간):